Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...
Clinical Trials Arena on MSN
Novartis to seek approval of anti-malaria drug on Phase III success
Based on the Phase III data, Novartis plans to seek regulatory approval from health authorities for GanLum, with the company ...
Zacks Investment Research on MSN
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
Novartis NVS reported positive top-line data from a late-stage study of its investigational new malaria treatment candidate, ...
Swiss pharma giant Novartis has announced positive results from KALUMA, a Phase III study for new malaria treatment KLU156 ...
Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant ...
Novartis plans to seek quick regulatory approvals from health authorities for the drug, known as GanLum, which would be the ...
Researchers are reporting two promising approaches to counteract malaria's growing drug resistance. Switzerland-based ...
Promising results from a new malaria drug offer hope against emerging drug resistance in Africa. In a clinical trial, ...
The best drug to fight malaria is facing increased resistance from the parasites it fights. Now there's an alternative in the ...
A new antimalarial drug developed by Novartis is as effective as existing treatments and could help tackle rising drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback